ribosomal protein L23a pseudogene 86Genealiases: []
Q-omics provides the consensus-scored RPL23AP86 profile across patient tissues and cancer cell-line models. RPL23AP86 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RPL23AP86 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, RPL23AP86 RNA expression shows 7,015 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, HNSC, and THYM as cancer lineages where RPL23AP86 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23AP86 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23AP86 survival associations across molecular data types. RPL23AP86 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23AP86 RNA expression–survival associations across cancer types. High RPL23AP86 expression shows unfavorable associations in LIHC, TGCT, HNSC and LUSC, but favorable associations in BLCA and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .012). Together, the overview and detailed table identify BLCA as the clearest survival context for RPL23AP86 RNA expression.
This table summarizes RPL23AP86 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL23AP86. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23AP86 shows higher tumor expression in HNSC, LUSC, BLCA, COAD, BRCA and LIHC. The HNSC box plot shows higher RPL23AP86 RNA expression in tumor versus normal tissue (log2 FC = +0.167, t-test p < 0.001).
This table shows molecular features associated with RPL23AP86 in patient tissues and cancer cell lines. In patient samples, RPL23AP86 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
